Nuclear factor-κB regulates expression of platelet phospholipase C-β2 (PLCB2)

Area of Science:

• Molecular Biology
• Hematology
• Immunology

Background:

• Phospholipase C (PLC)-β2 is crucial for platelet activation.
• The regulatory mechanisms of PLC-β2 expression in platelets and megakaryocytes (MKs) are not well understood.
• A patient with PLC-β2 deficiency exhibited normal PLCB2 coding sequence but reduced mRNA, suggesting transcriptional dysregulation.

Purpose of the Study:

• To investigate the mechanisms regulating PLC-β2 expression.
• To determine the role of a specific 13 bp deletion in the PLCB2 promoter region, which affects a nuclear factor-kappa B (NF-κB) binding site.
• To elucidate the functional impact of this variation on PLC-β2 expression and platelet function.

Main Methods:

• Analysis of a patient with PLC-β2 deficiency.
• Gel-shift assays to confirm NF-κB binding to the PLCB2 promoter.
• Luciferase reporter assays to assess promoter activity.
• siRNA knockdown and overexpression of NF-κB p65 subunit.
• Immunoblotting to quantify platelet PLC-β2 levels.

Main Results:

• A heterozygous 13 bp deletion in the PLCB2 5'-upstream region, encompassing an NF-κB binding site, was identified in a patient and three healthy subjects.
• NF-κB directly binds to the PLCB2 promoter region.
• The deletion significantly reduced PLCB2 promoter activity.
• NF-κB p65 subunit knockdown decreased PLCB2 expression, while p65 overexpression increased it.
• Platelet PLC-β2 levels positively correlated with p65 levels in healthy individuals.

Conclusions:

• Nuclear factor-kappa B (NF-κB) is a key regulator of PLC-β2 expression in megakaryocytes and platelets.
• This regulatory interaction is significant given the roles of PLC-β2 in platelet activation and NF-κB in inflammation and atherosclerosis.